The genes that were downregulated by IFN-β treatment were primarily enriched in cell cycle pathways, which also provides evidence to support the previously identified inhibitory role of IFN-β in cancer cells (Garrison et al. 1996; Ito et al. 2010; Sims et al. 2008). The gene discussed is IFNB1; the disease is cancer.